3.8 Article

Association Between Bio-Fermentation Derived Hyaluronic Acid and Healthcare Costs Following Knee Arthroplasty

期刊

CLINICOECONOMICS AND OUTCOMES RESEARCH
卷 14, 期 -, 页码 575-585

出版社

DOVE MEDICAL PRESS LTD
DOI: 10.2147/CEOR.S347512

关键词

bio-fermentation derived hyaluronic acid; healthcare costs; intra-articular hyaluronic acid; knee arthroplasty; readmissions

资金

  1. Ferring Pharmaceuticals Inc

向作者/读者索取更多资源

The study found that using bio-fermentation derived hyaluronic acid (BioHA) prior to knee arthroplasty does not increase overall healthcare costs and can reduce postoperative readmission rates and inpatient costs.
Background: Limiting access to intra-articular knee injections, including hyaluronic acid (HA), has been advocated as a cost-containment measure in the treatment of knee osteoarthritis. The association between presurgical injections and post-surgical complications such as early periprosthetic joint infection and revision remained to be investigated. This study evaluated pre- and post-surgical costs and rates of post-surgical complications in knee arthroplasty (KA) patients with or without prior HA use.Methods: Commercial and Medicare Supplemental Claims Data (IBM MarketScan Research Databases) from January 1, 2012 to December 31, 2018 were used to identify unilateral KA patients. Those who completed a course of bio-fermentation derived HA (BioHA) as the first-line HA therapy comprised of the test group (n = 4091), while the control group did not use HA prior to KA (n = 118,659). Using multivariable regression with propensity score (PS) weighting, overall healthcare costs, readmission rates, and revision rates were assessed at six months following KA.Results: Healthcare costs following KA were significantly lower for the Bio-HA group ($10,021 +/- $22,796) than No HA group ($12,724 +/- $32,966; PS p < 0.001). Bio-HA patients had lower readmission rates (8.9% vs 14.0%; PS p < 0.001) and inpatient costs per readmitted patient ($43,846 +/- $50,648 vs $50,533 +/- $66,150; PS p = 0.005). There were no differences in revision rate for any reason (Bio-HA: 0.78% vs No HA: 0.67%; PS p = 0.361) and with PJI (Bio-HA: 0.42% vs No HA: 0.33%; PS p = 0.192). Costs in the six months up to and including the KA were similar for both groups (Bio-HA: $49,759 +/- $40,363 vs No HA: $50,532 +/- $43,183; PSConclusion: Bio-HA use prior to knee arthroplasty did not appear to increase overall healthcare costs in the six months before and after surgery. Allowing access to HA injections provides a non-surgical therapeutic option without increasing cost or risk of postsurgical complications.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

3.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据